Details for Patent: 8,207,127
✉ Email this page to a colleague
Which drugs does patent 8,207,127 protect, and when does it expire?
Patent 8,207,127 protects KYPROLIS and is included in one NDA.
This patent has eighty-nine patent family members in twenty-seven countries.
Summary for Patent: 8,207,127
Title: | Compounds for enzyme inhibition |
Abstract: | Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. |
Inventor(s): | Smyth; Mark S. (Foster City, CA), Laidig; Guy J. (Menlo Park, CA) |
Assignee: | Onyx Technologies, Inc. (South San Francisco, CA) |
Application Number: | 13/334,544 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,207,127 |
Patent Claim Types: see list of patent claims | Use; Device; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 8,207,127
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | KYPROLIS IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY | ⤷ Sign Up | ||||
Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | KYPROLIS IS INDICATED IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY | ⤷ Sign Up | ||||
Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | KYPROLIS IS INDICATED IN COMBINATION WITH DARATUMUMAB PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY | ⤷ Sign Up | ||||
Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,207,127
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 1781688 | ⤷ Sign Up | PA2016010 | Lithuania | ⤷ Sign Up |
European Patent Office | 1781688 | ⤷ Sign Up | 93015 | Luxembourg | ⤷ Sign Up |
European Patent Office | 1781688 | ⤷ Sign Up | CA 2016 00014 | Denmark | ⤷ Sign Up |
European Patent Office | 1781688 | ⤷ Sign Up | 300805 | Netherlands | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |